Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

Funding for life science startups seeking to raise capital has been tight for the past four years. While there was optimism that 2025 may change the tide, we have not yet seen an ease in the flow of ...

Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

Leadership in pharma means questioning assumptions, amplifying diverse voices, and creating environments where authenticity ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...